Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659911 | 0.90 | KCNN4 (0.32) | — | |
| SCHEMBL7246414 | 0.73 | — | — | |
| SCHEMBL2657593 | 0.72 | GABRG2 (0.54) | RXRAGRIN1GRIN2B | |
| SCHEMBL2658746 | 0.72 | GABRA1 (0.36) | RXRAGRIN1GRIN2B | |
| SCHEMBL2659109 | 0.71 | GABRG2 (0.47) | RXRAGRIN1GRIN2B | |
| SCHEMBL2653692 | 0.66 | GABRA1 (0.40) | — | |
| SCHEMBL7668080 | 0.65 | GABRG2 (0.46) | — | |
| SCHEMBL7238741 | 0.65 | HCAR1 (0.34) | RXRAGRIN1GRIN2B | |
| SCHEMBL341480 | 0.64 | GABRG2 (0.54) | — | |
| SCHEMBL2659906 | 0.62 | MAPT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073717-A1 | Triazolo-pyridine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-04-17 | — | — | US | claimed |
| EP-1087968-A1 | TRIAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065904-A1 | TRIAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-23 | — | — | WO | claimed |
| US-20030073717-A1 | Triazolo-pyridine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-04-17 | — | — | US | disclosed |
| US-6479506-B1 | USEFUL IN THE THERAPY OF DELETERIOUS MENTAL STATES SUCH AS ANXIETY | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1087968-A1 | TRIAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065904-A1 | TRIAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073717-A1 | Triazolo-pyridine derivatives as ligands for GABA receptors | GABRA3, GABRA4, GABRA5 | RXRA 787/4885GRIN1 66/4885GRIN2B 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.